dbACP: A Comprehensive Database of Anti-Cancer Peptides

438 result(s) have been found!

Accession Name Sequence Source/Organism Mechanism Assay Type Cell Line Cancer Type Activity
dbacp00051 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 2.4% inhibition at 10-5 M
dbacp00052 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 7.5% inhibition at 10-4 M
dbacp00075 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 1.1% inhibition at 10-5 M
dbacp00076 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 1.2% inhibition at 10-4 M
dbacp00077 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 17.8% inhibition at 10-3 M
dbacp00096 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 7.7% inhibition at 10-4 M
dbacp00097 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 18.7% inhibition at 10-3 M
dbacp00149 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 21.2% inhibition at 10-3 M
dbacp00182 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 15.6% inhibition at 10-3 M
dbacp00216 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 22.8% inhibition at 10-3 M
dbacp00250 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 9.6% inhibition at 10-4 M
dbacp00251 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 29.9% inhibition at 10-3 M
dbacp00288 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 2.2% inhibition at 10-6 M
dbacp00289 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 7.1% inhibition at 10-5 M
dbacp00290 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 6.9% inhibition at 10-4 M
dbacp00291 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer 25.9% inhibition at 10-3 M
dbacp00304 Temporin-SHf FFFLSRIF* Sahara frog Apoptosis inducing MTT assay MCF-7 Not specified IC50 : 32.76 ± 1.528 µM
dbacp00342 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Epithelial cancer CC50 : 29.0 ± 3.7 μM
dbacp00343 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Chronic myeloid Leukemia CC50 : 29.0 ± 3.7 μM
dbacp00344 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Gastric cancer CC50 : 29.0 ± 3.7 μM
dbacp00345 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Breast cancer CC50 : 29.0 ± 3.7 μM
dbacp00346 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Cervical cancer CC50 : 29.0 ± 3.7 μM
dbacp00382 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Epithelial cancer CC50 : 37.5 ± 3.3 μM
dbacp00383 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Chronic myeloid Leukemia CC50 : 37.5 ± 3.3 μM
dbacp00384 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Gastric cancer CC50 : 37.5 ± 3.3 μM
dbacp00385 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Breast cancer CC50 : 37.5 ± 3.3 μM
dbacp00386 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Cervical cancer CC50 : 37.5 ± 3.3 μM
dbacp00460 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Epithelial cancer CC50 : 6.7 ± 0.7 μM
dbacp00461 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Chronic myeloid Leukemia CC50 : 6.7 ± 0.7 μM
dbacp00462 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Gastric cancer CC50 : 6.7 ± 0.7 μM
dbacp00463 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Breast cancer CC50 : 6.7 ± 0.7 μM
dbacp00464 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Cervical cancer CC50 : 6.7 ± 0.7 μM
dbacp00500 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Epithelial cancer CC50 : 15.2 ± 1.9 μM
dbacp00501 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Chronic myeloid Leukemia CC50 : 15.2 ± 1.9 μM
dbacp00502 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Gastric cancer CC50 : 15.2 ± 1.9 μM
dbacp00503 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Breast cancer CC50 : 15.2 ± 1.9 μM
dbacp00504 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Cervical cancer CC50 : 15.2 ± 1.9 μM
dbacp00593 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Epithelial cancer CC50 : 48.4 ± 0.7 μM
dbacp00594 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Chronic myeloid Leukemia CC50 : 48.4 ± 0.7 μM
dbacp00595 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Gastric cancer CC50 : 48.4 ± 0.7 μM
dbacp00596 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Breast cancer CC50 : 48.4 ± 0.7 μM
dbacp00597 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Cervical cancer CC50 : 48.4 ± 0.7 μM
dbacp00666 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Epithelial cancer CC50 : 15.1 ± 1.4 μM
dbacp00667 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Chronic myeloid Leukemia CC50 : 15.1 ± 1.4 μM
dbacp00668 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Gastric cancer CC50 : 15.1 ± 1.4 μM
dbacp00669 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Breast cancer CC50 : 15.1 ± 1.4 μM
dbacp00670 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Cervical cancer CC50 : 15.1 ± 1.4 μM
dbacp00775 A12L KWKSFLKTFKSLKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay MCF-7 Breast cancer IC50 : 5 µMo/L
dbacp00783 A12L/A20L KWKSFLKTFKSLKKTVLHTLLKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay MCF-7 Breast cancer IC50 : 6.2 µMo/L
dbacp00791 A12L/A20L/A23L KWKSFLKTFKSLKKTVLHTLLKLISS PeptideV13K Membrane disruption mechanism MTT/MTS assay MCF-7 Breast cancer IC50 : 5.7 µMo/L
dbacp00799 A20L KWKSFLKTFKSAKKTVLHTLLKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay MCF-7 Breast cancer IC50 : 5.1 µMo/L
dbacp00811 A4K14-citropin1.1 GLFAVIKKVASVIKGL Synthetic construct Cell membrane disintegration CCK-8 test MCF-7 Prostate cancer IC50 : 14.16 μM
dbacp00812 A4K14-citropin1.1 GLFAVIKKVASVIKGL Synthetic construct Cell membrane disintegration CCK-8 test MCF-7 Lung cancer IC50 : 14.16 μM
dbacp00819 AaeAP1 FLFSLIPSVIAGLVSAIRN Aeneas fattailed scorpion Not specified MTT assay MCF-7 Prostate cancer Not found
dbacp00823 AaeAP1 FLFSLIPSVIAGLVSAIRN Venom, Aeneas fattailed scorpion, Africa Membrane lysis MTT assay MCF-7 Non-tumourigenic mammary gland cancer MIC : 10−4 to 10−9 M
dbacp00827 AaeAP2 FLFSLIPSAIAGLVSAIRN Aeneas fattailed scorpion Not specified MTT assay MCF-7 Prostate cancer Not found
dbacp00831 AaeAP2 FLFSLIPSAIAGLVSAIRN Venom, Aeneas fattailed scorpion, Africa Membrane lysis MTT assay MCF-7 Non-tumourigenic mammary gland cancer MIC : 10−4 to 10−9 M
dbacp01142 Amphipathic peptide CT1 MKTQFVILIVAVVLLQLISHSEAFLGALWNVAKSVFGKRGLRNFDDLDDTFEPEMSEADLKYLQDLLR Scorpions, Morelos, located in South-Central Mexico (Mexican scorpion) Not specified MTT/MTS assay MCF-7 Breast cancer IC50 : 6.3-12.5 μM
dbacp01163 Antimicrobial peptide TsAP-1 MQIKHLITLFFLVLIVADQCSAFLSLIPSLVGGSISAFKGRRKREISAQIEQYKDLQKREAELEELLDRLPMY Brazilian scorpion Membrane disruption MTT Cell viability assay MCF-7 Human breast carcinoma IC50 : 0.83 - 2.0 μM
dbacp01187 APQQ NA Synthetic construct Cell metatstasis inhibition Transwell assay MCF-7 Breast cancer Not found
dbacp01391 Aurein-3.3 [Cleaved into: Aurein-3.3.1] GLFDIVKKIAGHIVSSI Southern bell frog Cell membrane disintegration One-dose and five-dose assay MCF7 Breast cancer IC50 : 5 μM
dbacp01919 BR-C CKLKNFAKGVAQSLLNKASKLSGQC Not found Inducing apoptosis Not specified MCF-7 Not specified IC50 : 45.72 μg/ml
dbacp01921 BR-D KLKNFAKGVAQSLLNKASCKLSGQC Not found Inducing apoptosis Not specified MCF-7 Not specified IC50 : 67.52 μg/ml
dbacp01974 Brevinin-2R KLKNFAKGVAQSLLNKASCKLSGQC Skin, Marsh frog, Europe Activates the lysosomal-mitochondrial death pathway; Involves autophagy-like cell death MTT-assay MCF-7 Breast adenocarcinoma LD50 : 10 – 15μg/ml
dbacp01975 Brevinin-2R KLKNFAKGVAQSLLNKASCKLSGQC Skin, Marsh frog, Europe Activates the lysosomal-mitochondrial death pathway; Involves autophagy-like cell death MTT-assay MCF-7 Breast adenocarcinoma LD50 : 20 – 25 μg/ml
dbacp01976 Brevinin-2R KLKNFAKGVAQSLLNKASCKLSGQC Skin, Marsh frog, Europe Activates the lysosomal-mitochondrial death pathway; Involves autophagy-like cell death MTT-assay MCF-7 Breast adenocarcinoma LD50 : 30 – 40 μg/ml
dbacp01983 Brevinin-2R KLKNFAKGVAQSLLNKASCKLSGQC Skin, Marsh frog, Europe Activates the lysosomal-mitochondrial death pathway; Involves autophagy-like cell death MTT-assay MCF-7 Breast adenocarcinoma LD50 : 10 – 15 µg/ml
dbacp01984 Brevinin-2R (BR-2R) KLKNFAKGVAQSLLNKASCKLSGQC Not found Inducing apoptosis Not specified MCF-7 Not specified IC50 : 24.11 μg/ml
dbacp01995 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay MCF-7 Breast cancer IC50 : 15.1 µg/ml
dbacp02053 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay MCF-7 Not specified IC50 : 15.1 µg/ml
dbacp02112 cMastoparan-C(cMP-C) CLNLKALLAVAKKILC Synthetic construct Apoptosis MTT assay MCF-7 Human breast cancer IC50 : 13.66 μM
dbacp02284 Cancer stem-like cells CD44 peptide-specific CTLs YIFYTFSTV,LILAVCIAV,SLLALALIL,IILASLLAL,WLIILASLL,VLLQTTTRM,GLVEDLDRT,TVGDSNSNV Cancer stem-like cells CD44 peptide-specific CTLs Cell membrane penetrating Not specified MCF-7 Breast cancer Not found
dbacp02285 Cancer stem-like cells EpCAM peptide-CTLs VVAGIVVLV,GLKAGVIAV,VLAFGLLLA,RTYWIIIEL,SMCWCVNTA,SMQGLKAGV,ILYENNVIT,LLLAAATAT Cancer stem-like cells EpCAM peptide-CTLs Inhibit tumor growth and induce specific immune response Not specified MCF-7 Hepatoma cancer Not found
dbacp02298 Carcinoembryonic antigen glypican-3 GPC3(298-306) EYILSLEEL Carcinoembryonic antigen glypican-3 GPC3(298-306) Immune response to tumor cell recognition Cytotoxicity assay MCF-7 Not specified Not found
dbacp02366 Cecropin B KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL Silkmoth Pore formation at the cytoplasmic membrane MTT/MTS assay MCF-7 Breast cancer IC50 : 42.5 µM
dbacp02369 Cecropin B KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL Silkmoth Pore formation at the cytoplasmic membrane MTT/MTS assay MCF-7R Breast cancer IC50 : 24.5 µM
dbacp02415 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Epithelial cancer CC50 : 15.3 ± 1.4 μM
dbacp02416 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Chronic myeloid leukemia CC50 : 15.3 ± 1.4 μM
dbacp02417 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Gastric cancer CC50 : 15.3 ± 1.4 μM
dbacp02418 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Breast cancer CC50 : 15.3 ± 1.4 μM
dbacp02419 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Cervical cancer CC50 : 15.3 ± 1.4 μM
dbacp02475 Chickpea peptide ADLPGLK Plant sources Inducing apoptosis SRB assay MCF-7 Human endometrial cancer IC50 : 110.3 ± 2.97µM
dbacp02546 Conotoxin Cl14.1a (Conotoxin Cal14.1a) MNVTAMFIVLLLTMPLTDGFNIRAINGGELFGLVQRDAGNALDHGFYRRGDCPPWCVGARCRAEKC California cone Apoptosis Not specified MCF-7 Breast cancer Not found
dbacp02629 D-SVS-1 kvkvkvkvPptkvkvkvk Synthetic peptide Disruption of cell membranes MTT/MTS assay MCF-7 Breast cancer IC50 : 4.7 ± 0.4 µM
dbacp02637 Decoralin SLLSLIRKLI Solitary eumenine wasp Mediate necrosis MTT assay MCF-7 Breast cancer IC50 : 12.5 μmolL−1
dbacp02645 Defensin-like protein (Sesquin) KTCENLADTY Yard-Long bean Anti-proliferative action MTT assay MCF-7 Leukemia MIC : 0.25 μg/ml
dbacp02654 Dermaseptin PS4 MDILKKSIFLVLFLGLVSLSICEEEKRENEDEEKQEDDEQSEEKRALWKTLLKHVGKAAGKAALNAVTDMVNQGEQ Sauvage's leaf frog Membrane disruption Lactate dehydrogenase (LDH) cytotoxicity assay, MTT assay MCF-7 Breast cancer MIC : 10−9 to 10−4 M
dbacp02660 Dermaseptin-B3 ALWKnMLKGIGKLAGQAALGAVKTLVGA South American frog, Giant leaf frog Apoptosis inducing Thymidine Incorporation assay MCF-7 Breast cancer Not found
dbacp02661 Dermaseptin-B4 ALWKDILKNVGKAAGKAVLNTVTDMVNQ Giant leaf frog Apoptosis inducing Thymidine Incorporation assay MCF-7 Breast cancer Not found
dbacp02678 Dermaseptin-PH ALWKEVLKNAGKAALNEINNLVQ Northern orange-legged leaf frog Cell membrane permeabilization Bioactivity assessment assay, MTT cell proliferation assay MCF-7 Not specified IC50 : 0.69 μM
dbacp02683 Dermaseptin-PH ALWKEVLKNAGKAALNEINNLV Orange-legged leaf frog, Northern orange-legged leaf frog, South America Cell membrane permeabilization MTT cell proliferation assay MCF-7 Lung cancer IC50 : 0.69 μM
dbacp02689 Dermaseptin-PH MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ Northern orange-legged leaf frog Disruption of cell membranes MTT assay, Lactate dehydrogenase (LDH) assay MCF-7 Breast cancer IC50 : 17.44 - 49.51 μM
dbacp02693 Dermaseptin-PH (DRS-PH) MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ Northern orange-legged leaf frog Disruption of cell membranes MTT assay MCF-7 Brain tumor IC50 : 7.44 μM
dbacp02694 Dermaseptin-PH (DRS-PH) MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ Northern orange-legged leaf frog Disruption of cell membranes MTT assay MCF-7 Breast cancer IC50 : 7.44 μM
dbacp02695 Dermaseptin-PH (DRS-PH) MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ Northern orange-legged leaf frog Disruption of cell membranes MTT assay MCF-7 pancreatic cancer IC50 : 7.44 μM
dbacp02696 Dermaseptin-PH (DRS-PH) MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ Northern orange-legged leaf frog Disruption of cell membranes MTT assay MCF-7 Lung cancer IC50 : 7.44 μM
dbacp02697 Dermaseptin-PH (DRS-PH) MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ Northern orange-legged leaf frog Disruption of cell membranes MTT assay MCF-7 Prostate cancer IC50 : 7.44 μM
dbacp02730 Dermaseptin-PS4 ALWKTLLKHVGKAAGKAALNAVTDMVNQ Waxy monkey tree frog Membrane disruption Lactate dehydrogenase (LDH) cytotoxicity assay, MTT assay MCF-7 Breast cancer MIC : 10−9 to 10−4 M
dbacp02732 Dermaseptin-PT9 GLWSKIKDAAKTAGKAALGFVNEMV Brownbelly leaf frog Disruption of cell membranes MTT assay, Lactate dehydrogenase (LDH) assay MCF-7 Breast cancer IC50 : 8.64 - 18.51 μM
dbacp02737 Dermaseptin-PT9 GLWSKIKDAAKTAGKAALGFVNEMV Skin secretion, Brownbelly leaf frog, Purchased in Peru, South America Disruption of cell membranes MTT assay, Lactate dehydrogenase (LDH) assay MCF-7 Breast cancer IC50 : 8.64 - 18.51 μM
dbacp02745 Dex-(KW)3 KWKWKW Synthetic Cell membrane disruption MTT/MTS assay MCF-7 Breast cancer At 10 µM 35-40% viablity
dbacp02759 Dimer of peptide-paclitaxel conjugate (K-Aib-C(CH2CO-2'-Pac))2 Synthetic peptide paclitaxel conjugate Not specified MTT/MTS assay MCF-7 Breast cancer IC50 : 0.62 nM
dbacp02815 DRS B3 ALWKnMLKGIGKLAGQAALGAVKTLVGA Dermaseptins B Apoptosis inducing Thymidine incorporation assay MCF-7 Breast cancer Cytotoxicity :12 µM
dbacp02816 DRS B4 ALWKDILKNVGKAAGKAVLNTVTDMVNQ Dermaseptins B Apoptosis inducing Thymidine incorporation assay MCF-7 Breast cancer Cytotoxicity :15 µM
dbacp02817 DRS S1 ALWKTMLKKLGTMALHAGKAALGAAADTISQGTQ Dermaseptins B Apoptosis inducing Thymidine incorporation assay MCF-7 Breast cancer Not found
dbacp02829 Elastin derived peptide VGVAPG Elastin derived Apoptosis inducing Cell viability assay MCF-7 Breast cancer Not found
dbacp02931 Figainin 1 FIGTLIPLALGALTKLFK Chaco tree frog Membrane disruption and cell lysis MTT/MTS assay MCF Murine Melanoma IC50 : 13.7 µM
dbacp02939 Figainin 1 MAFLKKSLFLVLFLGLVSLSIGEEEKREEEEKNEEGANQEENAENKEKRFIGTLIPLALGALTKLFKG Chaco tree frog Anti-proliferative action MTT/MTS assay MCF Skin cancer IC50 : 13.7 µM
dbacp02940 Figainin 1 MAFLKKSLFLVLFLGLVSLSIGEEEKREEEEKNEEGANQEENAENKEKRFIGTLIPLALGALTKLFKG Chaco tree frog Anti-proliferative action MTT/MTS assay MCF Breast cancer IC50 : 13.7 µM
dbacp02941 Figainin 1 MAFLKKSLFLVLFLGLVSLSIGEEEKREEEEKNEEGANQEENAENKEKRFIGTLIPLALGALTKLFKG Chaco tree frog Anti-proliferative action MTT/MTS assay MCF Cervical cancer IC50 : 13.7 µM
dbacp02947 Figainin 1 FIGTLIPLALGALTKLFK Skin secretions, Chaco tree frog, South America Membrane disruption MTT/MTS assay MCF Murine melanoma IC50 : 13.7 µM
dbacp02950 Figainin 2 FLGAILKIGHALAKTVLPMVTNAFKPKQ Skin secretions, Chaco tree frog, South America Cell membrane interaction; Necrosis; Apoptosis MTT/MTS assay MCF-7 Murien melanoma IC50 : 15.3 µM
dbacp02953 Figainin 2 MAFLKKSLFLVLFLGIVSLSVCEEEKREGEEKEEKREEEEGKEENEDGNEEHKEKRFLGAILKIGHALAKTVLPMVTNAFKPKQ Chaco tree frog Necrosis; Apoptosis MTT/MTS assay MCF-7 Skin cancer IC50 : 15.3 µM
dbacp02954 Figainin 2 MAFLKKSLFLVLFLGIVSLSVCEEEKREGEEKEEKREEEEGKEENEDGNEEHKEKRFLGAILKIGHALAKTVLPMVTNAFKPKQ Chaco tree frog Necrosis; Apoptosis MTT/MTS assay MCF-7 Breast cancer IC50 : 15.3 µM
dbacp03035 Galaxamide derivative (Compound 3) cyclo(WnMLLLnML) Marine invertebrates Inducing apoptosis MTT assay MCF-7 Breast cancer IC50 : 1.72 ± 0.85 μg/mL
dbacp03039 Galaxamide derivative Compound 1 cyclo(FnMLLLnML) Marine invertebrates Inducing apoptosis MTT assay MCF-7 Breast cancer IC50 : 4.76 ± 1.36 μg/mL
dbacp03043 Galaxamide derivative Compound 2 cyclo(NAl-nMLLLnML) Marine invertebrates Inducing apoptosis MTT assay MCF-7 Breast cancer IC50 : 3.16 ± 0.92 μg/mL
dbacp03061 GGN6 FLPLLAGLAANFLPTIICKISYKC Skin of a Korean frog, wrinkled frog Induce apoptosis MTT/MTS assay MCF-7 Breast cancer IC50 : 4.88 µg/ml
dbacp03292 HECI TVLRGCWTFSFPPKPCI Hylarana erythraea Cell membrane disintegration MTT anti-proliferation assay MCF-7 Breast cancer MIC : 1µM
dbacp03367 Ichthyophthirius multifiliis (strain G5) B4 LKKLFKKILKYL White spot disease (strain G5) B4 Apoptosis inducing; Penetration of the cell membrane MTT assay MCF-7 Breast cancer MIC : 5 μM
dbacp03369 Ichthyophthirius multifiliis (strain G5) B8 LKKLFKKILKY White spot disease (strain G5) B8 Apoptosis inducing; Penetration of the cell membrane MTT assay MCF-7 Breast cancer MIC : 7 μM
dbacp03371 Ichthyophthirius multifiliis BP100 KKLFKKILKYL White spot disease BP100 Apoptosis inducing; Penetration of the cell membrane MTT assay MCF-7 Breast cancer MIC : 25 μM
dbacp03485 K8, 23-DPT9 MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ Northern orange-legged leaf frog Disruption of cell membranes MTT assay MCF-7 Brain tumor IC50 : 8.64μM
dbacp03486 K8, 23-DPT9 MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ Northern orange-legged leaf frog Disruption of cell membranes MTT assay MCF-7 Breast cancer IC50 : 8.64μM
dbacp03487 K8, 23-DPT9 MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ Northern orange-legged leaf frog Disruption of cell membranes MTT assay MCF-7 Pancreatic cancer IC50 : 8.64μM
dbacp03488 K8, 23-DPT9 MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ Northern orange-legged leaf frog Disruption of cell membranes MTT assay MCF-7 Lung cancer IC50 : 8.64μM
dbacp03489 K8, 23-DPT9 MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ Northern orange-legged leaf frog Disruption of cell membranes MTT assay MCF-7 Prostate cancer IC50 : 8.64μM
dbacp03533 L-amino acid oxidase (CC-LAAO) (LAO) (EC 1.4.3.2) MNVFFMFSLLFLAALESCADDKNPLEEEFFEADYEEFLLIAKNGLQQTSNPKRVVIVGAGMSGLSAAYVLAKTGHEVILLEASERVGGRVSTYRNDQEGWYANLGPMRLPERHRIVREYIRKFGLQLNEFSQENENAWYFIKNIRKRVGEVNKDPGVLEYPVKPSEKGKSAPQLYRDSLQKIIEEYGRSNCSYILNKYDTYSTKDYLIKEGNLSPGAVDMVGDLLNEDSGYYVSFIESLKPDDIFAYENRFDEIVGGFDKLPTSMYQAIQEKVRLNVRVIKIQQDVKEVTVTYQTPAKNLSYVTADYVIVCTTSGAARRIKFEPPLPLKKAHALRSVHYRSGTKIFLTCTKKFWEDDGIHGGKSITDRPSRLIHYPNHNFPNGIGVLVIFTIADDADFFLALDNKTIADIVIHDLSLIHQLPKEKIRDLCYVSMIQKWSLDKYAMGGITTFTPYQFQHFSEALTAPVDRIYFAGEYTAQAHGWIDSTIKSGLTAARDVNRASENPSGIHLSNDNEL Horned desert vip Cytotoxic effects MTT assay MCF-7 Not found IC50 : 4 µg/mL
dbacp03572 L17A KWKSFLKTFKSAKKTVAHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay MCF-7 Breast cancer IC50 : > 83.6 µMo/L
dbacp03580 L17A/L21A KWKSFLKTFKSAKKTVAHTAAKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay MCF-7 Breast cancer IC50 : > 83.6 µMo/L
dbacp03591 L21A KWKSFLKTFKSAKKTVAHTAAKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay MCF-7 Breast cancer IC50 : 70.8 µMo/L
dbacp03615 L6A KWKSFAKTFKSAKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay MCF-7 Breast cancer IC50 : 62.3 µMo/L
dbacp03623 L6A/L17A KWKSFAKTFKSAKKTVAHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay MCF-7 Breast cancer IC50 : >83.6 µMo/L
dbacp03742 LfcinB (Bovine lactoferricin) FKCRRWQWRM Not found Inducing apoptosis MTT assay MCF-7 Leukemia Not found
dbacp03753 LHRH–BH3 peptide luteinizing hormone-releasing hormone (LHRH) QHWSYGLRPGMGQVGRQLAIIGDDINRRY Effectors (BAK, BAX) Inducing apoptosis Cytotoxicity assay, MTT assay MCF-7 Human breast cancer Not found
dbacp04129 LK-L1C/K6W/L8C CKKLLWLCKKLLKLAG Not found Inducing apoptosis MTS assay MCF-7 Not specified Not found
dbacp04130 LK1 (Temporin-1CEa Analog peptide) FVDLKKIANIINSIFKK Synthetic construct Cell membrane disintegration MTT-assay MCF-7 Breast cancer IC50 : 20.97 µM
dbacp04133 LK2(5) (Temporin-1CEa Analog peptide) FKDLKKIANIINSIFKK Synthetic construct Cell membrane disintegration MTT-assay MCF-7 Breast cancer IC50 : 44.7 µM
dbacp04136 LK2(6) (Temporin-1CEa Analog peptide) FVKLKKIANIINSIFKK Synthetic construct Cell membrane disintegration MTT-assay MCF-7 Breast cancer IC50 : 15.54 µM
dbacp04139 LK2(6)A(L) (Temporin-1CEa Analog peptide) FVKLKKILNIINSIFKK Synthetic construct Cell membrane disintegration MTT-assay MCF-7 Breast cancer IC50 : 9.01 µM
dbacp04142 LK2(6)AN(2L) (Temporin-1CEa Analog peptide) FVKLKKILNIILSIFKK Synthetic construct Cell membrane disintegration MTT-assay MCF-7 Breast cancer IC50 : 11 µM
dbacp04145 LK3 (Temporin-1CEa Analog peptide) FKKLKKIANIINSIFKK Synthetic construct Cell membrane disintegration MTT-assay MCF-7 Breast cancer IC50 : 27.72 µM
dbacp04148 LL 37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES Also known human cathelicidin Plasma membrane perturbations MTT/MTS assay MCF-7 Breast cancer LC50 : 21 at 100 µM
dbacp04311 Lunasin SKWQHQQDSCRKQLQGVNLTPCEKHIMEKIQGRGDDDDDDDDD Soyabean Cell membrane degradation TUNEL DNA fragmentation assay MCF-7 Breast cancer Not found
dbacp04314 Lunasin SKWQHQQDSCRKQLQGVNLTPCEKHIMEKIQGRGDDDDDDDDD Soyabean Apoptosis inducing; Anti-proliferative MTT/MTS MCF-7 Not specified IC50 : 431.9 µM
dbacp04495 Magainin 2 GIGKFLHSAKKFGKAFVGEIMNS African clawed frog Dissipate ion gradients; Induce osmotic lysis; Membrane damage Trypan blue assay MCF-7 Breast cancer IC50 : >200 µg/ml
dbacp04513 Magainin A AIGKFLHSAKKFGKAFVGEIMNS African clawed frog Dissipate ion gradients; Induce osmotic lysis; Membrane damage Trypan blue assay MCF-7 Breast cancer IC50 : 49 µg/ml
dbacp04523 Magainin B GIGKFLHAAKKFAKAFVAEIMNS African clawed frog Dissipate ion gradients; Induce osmotic lysis; Membrane damage Trypan blue assay MCF-7 Breast cancer IC50 : 37 µg/ml
dbacp04539 Magainin G GIGKFLHSAKKFAKAFVAEIMNS African clawed frog Dissipate ion gradients; Induce osmotic lysis; Membrane damage Trypan blue assay MCF-7 Breast cancer IC50 : 42 µg/ml
dbacp04543 Malanin chain A DYPKLTFTTS Plant sources Inducing apoptosis MTT assay MCF-7 Leukemia IC50 : 11.20 ± 0.02 nM
dbacp04549 Malanin chain B DETCTDEEFN Plant sources Inducing apoptosis MTT assay MCF-7 Leukemia IC50 : 11.20 ± 0.02 nM
dbacp04553 MAP-04-03 KWLRRVWRWWR Analogs of Ixosin-B amide Disrupting the integrity of cell membrane MTT/MTS assay MCF-7 Breast cancer Cell viability : >80% at 25 µM
dbacp04554 MAP-04-03 KWLRRVWRWWR Analogs of Ixosin-B amide Disrupting the integrity of cell membrane MTT/MTS assay MCF-7 Breast cancer Cell viability : ~50% at 50 µM
dbacp04555 MAP-04-03 KWLRRVWRWWR Analogs of Ixosin-B amide Disrupting the integrity of cell membrane MTT/MTS assay MCF-7 Breast cancer Cell viability : <40% at 75 µM
dbacp04556 MAP-04-03 KWLRRVWRWWR Analogs of Ixosin-B amide Disrupting the integrity of cell membrane MTT/MTS assay MCF-7 Breast cancer Cell viability : >20% at 100 µM
dbacp04557 MAP-04-03 KWLRRVWRWWR Analogs of Ixosin-B amide Disrupting the integrity of cell membrane MTT/MTS assay MCF-7 Breast cancer Cell viability : ~100% at 25 µM
dbacp04558 MAP-04-03 KWLRRVWRWWR Analogs of Ixosin-B amide Disrupting the integrity of cell membrane MTT/MTS assay MCF-7 Breast cancer IC50 :61.5 µM
dbacp04559 MAP-04-04 KRLRRVWRRWR Analogs of Ixosin-B amide Disrupting the integrity of cell membrane MTT/MTS assay MCF-7 Breast cancer Cell viability : > 80% at 50 µM
dbacp04560 MAP-04-04 KRLRRVWRRWR Analogs of Ixosin-B amide Disrupting the integrity of cell membrane MTT/MTS assay MCF-7 Breast cancer Cell viability : > 80% at 75 µM
dbacp04561 MAP-04-04 KRLRRVWRRWR Analogs of Ixosin-B amide Disrupting the integrity of cell membrane MTT/MTS assay MCF-7 Breast cancer Cell viability : > 80% at 100 µM
dbacp04563 Mastoparan INLKALAALAKKIL Venom base Inducing apoptosis Not specified MCF-7 Not specified IC50 : 432.5 ± 10.9 µM
dbacp04577 Mastoparan-C LNLKALLAVAKKIL European hornet Apoptosis MTT assay MCF-7 Human Breast cancer IC50 : 1.4 μM
dbacp04582 Mastoparan-Cimals. XXA; UCLL1c) LNLKALLAVAKKIL Venom, the European Hornet Inducing apoptosis MTT cell viability assay and Lactate dehydrogenase (LDH) leakage assay MCF-7 Breast cancer MIC : 6.26 - 36.65 μM
dbacp04588 Mastoparan-Cimals. XXA; UCLL1c) LNLKALLAVAKKIL Venom, the European Hornet Inducing apoptosis MTT cell viability assay and Lactate dehydrogenase (LDH) leakage assay MCF-7 Breast cancer IC50 : < 4 μM
dbacp04713 mt_E17L/L22 W/P27A LTFSDWWKLLAE MDM3 Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer IC50 : 15.1 µM
dbacp04714 mt_L22 W/P27A ETFSDWWKLLAE MDM2 Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer IC50 : 16.3 µM
dbacp04715 mt_S20A/L22 W/P27A ETFADWWKLLAE MDM5 Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer IC50 : 8.7 µM
dbacp04716 mt_T18S/L22 W/P27A ESFSDWWKLLAE MDM4 Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer IC50 : 27 µM
dbacp04929 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MCF-7 Breast cancer 70% Cytotoxic at 50 µM
dbacp04930 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MCF-7-TX400 Breast cancer 60-70% Cytotoxic at 50 µM
dbacp04931 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL-NH2 PseudopWinter flounder Cell membrane damage MTT/MTS assay MCF-7-TX400 Breast cancer 60-70% Cytotoxic at 50 µM
dbacp04952 NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MCF-7 Breast cancer 70% Cytotoxic at 50 µM
dbacp04974 NRC-07 RWGKWFKKATHVGKHVGKAALTAYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MCF-7 Breast cancer 70% Cytotoxic at 50 µM
dbacp04975 NRC-07 RWGKWFKKATHVGKHVGKAALTAYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MCF-7-TX400 Breast cancer 60-70% Cytotoxic at 50 µM
dbacp04996 NRC-13 GWRTLLKKAEVKTVGKLALKHYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MCF-7 Breast cancer 0% Cytotoxic at 50 µM
dbacp04997 NRC-13 GWRTLLKKAEVKTVGKLALKHYL Skin mucous secretion of winter flounder Cell membrane damage MTT/MTS assay MCF-7-TX400 Breast cancer ~5% Cytotoxic at 50 µM
dbacp04998 NuBCP-9 FSRSLHSLL Not found Inducing apoptosis Not specified MCF-7 Not specified Not found
dbacp05000 NuBCP-9 (DR8) FSRSLHSLLRRRRRRRR Not found Inducing apoptosis XTT assat MCF-7 Breast cancer IC50 : 7.11 μM
dbacp05023 Peptide P KWKSFLKTFKSAKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay MCF-7 Breast cancer IC50 : 15.8 µMo/L
dbacp05036 p120RasGAP (317-326) WMWVTNLRTD Not found Inducing apoptosis Luciferase assay MCF-7 Human malignant mesothelomia Not found
dbacp05037 P160 VPWMEPAYQRFL Not found Apoptosis inducing MTT cytotoxicity assay MCF-7 Breast cancer IC50 : 14.2 ± 1.5 μM
dbacp05080 p53-C terminal peptide GSRAHSSHLKSKKGQSTSRHKK Not found Inducing apoptosis Annexin V-FITC Binding assay MCF-7 Breast cancer Not found
dbacp05081 p53-C terminal peptide GSRAHSSHLKSKKGQSTSRHKK Not found Inducing apoptosis Annexin V-FITC Binding assay MCF10-2A Breast cancer Not found
dbacp05106 PA10 RQIKIWFQNRRMKWKKGGGGNNETTSIQIAGSLHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay MCF10A Breast cancer MIC : 10 μM
dbacp05110 PA15 RQIKIWFQNRRMKWKKGGSLSAACHEQWSLGAQHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay MCF10A Breast cancer MIC : 10 μM
dbacp05114 PA2 RQIKIWFQNRRMKWKKGGATRPRVDTQPELCGMHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay MCF10A Breast cancer MIC : 10 μM
dbacp05118 PA3 RQIKIWFQNRRMKWKKGGDCLCISRRARLLRATHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay MCF10A Breast cancer MIC : 10 μM
dbacp05122 PA38 RQIKIWFQNRRMKWKKGGKYNGRFTTHHLLHLLNHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay MCF10A Breast cancer MIC : 10 μM
dbacp05126 PA49 RQIKIWFQNRRMKWKKGGAGVYTFLVGADNRGWEHHHHHH Synthetic construct Cell proliferation inhibition; Cell penetration; Apoptosis Cell viability assay MCF10A Breast cancer MIC : 10 μM
dbacp05250 Pep27 MRKEFHNVLSSGQLLADKRPARDYNRK Pneumococcus Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer IC50 : > 70 µM
dbacp05255 Pep27 MRKEFHNVLSSGQLLADKRPARDYNRK Not found Inducing apoptosis MTT assay MCF-7 Breast cancer IC50 : > 70 µM
dbacp05256 Pep27 MRKEFHNVLSSGQLLADKRPARDYNRK Pneumococcus Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer IC50 : > 70 µM
dbacp05261 Pep27 anal1 MWKWFHNVLSSWQLLADKRPARDYNRK Not found Inducing apoptosis MTT assay MCF-7 Breast cancer IC50 : 55 µM
dbacp05266 Pep27 anal2 MWKWFHNVLSWWWLLADKRPARDYNRK Not found Inducing apoptosis MTT assay MCF-7 Breast cancer IC50 : < 10 µM
dbacp05271 Pep27 anal3 MRKWFHNVLSSGQLLADKWPAWDYNRK Not found Inducing apoptosis MTT assay MCF-7 Breast cancer IC50 : 38 µM
dbacp05276 Pep27 anal4 MWKEFHNVLSSGQLLADKRWARWYNRW Not found Inducing apoptosis MTT assay MCF-7 Breast cancer IC50 : 29 µM
dbacp05281 Pep27 anal5 MWKWFHNVLSSGQLLADKWWAWWYNWW Not found Inducing apoptosis MTT assay MCF-7 Breast cancer IC50 : > 70 µM
dbacp05286 Pep27anal1 MWKWFHNVLSSWQLLADKRPARDYNRK Pneumococcus Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer IC50 : 55 µM
dbacp05291 Pep27anal2 MWKWFHNVLSWWWLLADKRPARDYNRK Pneumococcus Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer IC50 : < 10 µM
dbacp05296 Pep27anal3 MRKWFHNVLSSGQLLADKWPAWDYNRK Pneumococcus Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer IC50 : 38 µM
dbacp05301 Pep27anal4 MWKEFHNVLSSGQLLADKRWARWYNRW Pneumococcus Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer IC50 : 29 µM
dbacp05306 Pep27anal5 MWKWFHNVLSSGQLLADKWWAWWYNWW Pneumococcus Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer IC50 : >70 µM
dbacp05403 Peptide Glycyrrhetinic Acid Based Derivatives (compound 5) GGGG Not found Inducing apoptosis Not specified MCF-7 Cervical cancer IC50 : 5.0 ± 0.3 µg/mL
dbacp05484 Pexiganan GIGKFLKKAKKFGKAFVKILKK Analog of African clawed frog Plasma membrane perturbations MTT/MTS assay MCF-7 Breast cancer LC50 : 8 at 100 µM
dbacp05534 Phylloseptin-PBa1 FLSLIPHIASGIASLVKNF Burmeister's leaf frog, Brazil, South America Disruption of cell membranes MTT cell viability assay MCF-7 Breast cancer IC50 : approx. 0.29 µM
dbacp05545 Phylloseptin-PBa2 FLSLLPHIASGIASLVSKF Burmeister's leaf frog, Brazil, South America Disruption of cell membranes MTT cell viability assay MCF-7 Breast cancer IC50 : approx. 0.50 µM
dbacp05552 Phylloseptin-PHa FLSLIPAAISAVSALANHF Northern orange-legged leaf frog Disruption of the membrane MTT assay, Lactate dehydrogenase (LDH) assay MCF-7 Human breast cancer LD50 : < 5 µM
dbacp05665 Protein GPR15LG (Antimicrobial peptide with 57 amino acid residues) (AP-57) (Antimicrobial peptide-57) (Colon-derived SUSD2 binding factor) (CSBF) (Protein GPR15 ligand) (Protein GPR15L) (Secreted protein C10orf99) MRLLVLSSLLCILLLCFSIFSTEGKRRPAKAWSGRRTRLCCHRVPSPNSTNLKGHHVRLCKPCKLEPEPRLWVVPGALPQV Human Cytotoxic effects SDS-PAGE assay MCF-7 Colorectal cancer Not found
dbacp05712 PTP1 LLAGLAANFLPTIICKISYKC Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay MCF-7 Breast cancer IC50 : >100 µg/ml
dbacp05717 PTP2 FAGLAANFLPTIICKISYKC Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay MCF-7 Breast cancer IC50 : >100 µg/ml
dbacp05722 PTP4 FLKLLKKLAAKFLPTIICKISYKC Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay MCF-7 Breast cancer IC50 : 18.1 µg/ml
dbacp05727 PTP5 FLKLLKKLAAKLF Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay MCF-7 Breast cancer IC50 : 5.43 µg/ml
dbacp05732 PTP6 FLKLLKKLAAKLF Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay MCF-7 Breast cancer IC50 : 17.56 µg/ml
dbacp05737 PTP7 FLGALFKALSKLL Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay MCF-7 Breast cancer IC50 : 5.25 µg/ml
dbacp05742 PTP8 FLKLLAGLLKNFA Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay MCF-7 Breast cancer IC50 : 32.23 µg/ml
dbacp05812 R2PLx-22 GIMDTVKNAAKNLAGQLLDKLK Not found Inducing apoptosis MTT and LDH assay MCF-7 Lung cancer IC50 : 109.30 µM
dbacp05813 R2PLx-22 GIMDTVKNAAKNLAGQLLDKLK Not found Inducing apoptosis MTT and LDH assay MCF-7 Prostate cancer IC50 : 109.30 µM
dbacp05814 R2PLx-22 GIMDTVKNAAKNLAGQLLDKLK Not found Inducing apoptosis MTT and LDH assay MCF-7 Breast cancer IC50 : 109.30 µM
dbacp05815 R2PLx-22 GIMDTVKNAAKNLAGQLLDKLK Not found Inducing apoptosis MTT and LDH assay MCF-7 Glioma IC50 : 109.30 µM
dbacp05863 RA-V cyclopeptideRA-V-,cyclo(YAAYAY) Plant sources Inducing apoptosis MTT assay MCF-7 Breast cancer Not found
dbacp05873 Radical SAM domain protein MEAVLYVTRKCNLSCGHCIVDKEDNSDLPTDKVETLASDYPIDRTILSGGEPFLHDNFEELVALVPEPTVLSNGLVLSDEEYVGENSDMLEELNGIQLSVEGKEETTDARRGEGVWDRVMEAHQNLSEIGVESYLRSTYSREMMEEVGELMEFCDAEGISLVLFPEIGKPPLSPTENASFFDYAVEKGVVVATPDFHSYIGEGGECPAARTRISVDVNGEIYPCQFNWDYCLGEVGDEWGLIESRIERFDRTEPVPRTCSRCDFANKCRGCGVADTWSGCPIARGLSHSESPSRRPLKRVQETMNTLEDVGAPRGCHGC Uncultured archaeon Apoptosis inducing MTT assay MCF-7 Breast cancer MIC : 42% ± 8.1 μM
dbacp05893 Ranatuerin-2PLx GIMDTVKNAAKNLAGQLLDKLKCKITAC Not found Inducing apoptosis MTT and LDH assay MCF-7) Lung cancer IC50 : 20.19 µM
dbacp05894 Ranatuerin-2PLx GIMDTVKNAAKNLAGQLLDKLKCKITAC Not found Inducing apoptosis MTT and LDH assay MCF-7) Prostate cancer IC50 : 20.19 µM
dbacp05895 Ranatuerin-2PLx GIMDTVKNAAKNLAGQLLDKLKCKITAC Not found Inducing apoptosis MTT and LDH assay MCF-7) Breast cancer IC50 : 20.19 µM
dbacp05896 Ranatuerin-2PLx GIMDTVKNAAKNLAGQLLDKLKCKITAC Not found Inducing apoptosis MTT and LDH assay MCF-7) Glioma IC50 : 20.19 µM
dbacp05905 Ranatuerin-2PLx GIMDTVKNAAKNLAGQLLDKLKCKITAC Gram-negative purple non-sulfur bacteria Inducing apoptosis MTT Cell viability assay and Lactate dehydrogenase (LDH) leakage assay MCF-7 Human breast cancer IC50 : 20.19 µM
dbacp05910 Ranatuerin-2PLx GIMDTVKNAAKNLAGQLLDKLKCSITAC Skin secretions, the pickerel frog, North America Inducing apoptosis MTT Cell viability assay and Lactate dehydrogenase (LDH) leakage assay MCF-7 Breast cancer IC50 : 20.19 µM
dbacp05961 RGD-mda-7 MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSGAQGQEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQNVSDAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLANNFVLIVSQLQPSQENEMFSIRGDSAHRRFLLFRRAFKQLDVEAALTKALGEVDILLTWMQKFYKL Derived from wtmda-7/IL-24 by insertion or a glycine residue between Arg(164) and Asp(165). Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer Cell viability(% of control):0.5 at concentration 4 µg/ml
dbacp05963 RGD-mda-7 MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSGAQGQEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQNVSDAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLANNFVLIVSQLQPSQENEMFSIRGDSAHRRFLLFRRAFKQLDVEAALTKALGEVDILLTWMQKFYKL Derived from wtmda-7/IL-24 by insertion or a glycine residue between Arg(164) and Asp(165). Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer Apoptotic rate(%): >70% at concentration of 8 µg/ml
dbacp06000 S−24-R2PLx GIMDTVKNAAKNLAGQLLDKLKCSITAC Not found Inducing apoptosis MTT and LDH assay MCF-7 Lung cancer IC50 : 316.90 µM
dbacp06001 S−24-R2PLx GIMDTVKNAAKNLAGQLLDKLKCSITAC Not found Inducing apoptosis MTT and LDH assay MCF-7 Prostate cancer IC50 : 316.90 µM
dbacp06002 S−24-R2PLx GIMDTVKNAAKNLAGQLLDKLKCSITAC Not found Inducing apoptosis MTT and LDH assay MCF-7 Breast cancer IC50 : 316.90 µM
dbacp06003 S−24-R2PLx GIMDTVKNAAKNLAGQLLDKLKCSITAC Not found Inducing apoptosis MTT and LDH assay MCF-7 Glioma IC50 : 316.90 µM
dbacp06119 SK84 SQLGDLGSGAGQGGGGGGSIRAAGGAFGKLEAAREEEFFYKKQKEQLERLKNDQIHQAEFHHQQIKEHEEAIQRHKDFLNNLHK Fruit fly Cell membrane disintegration MTS/PES colorimetric assay MCF-7 Liver cancer IC50 : 50 μM
dbacp06120 SK84 SQLGDLGSGAGQGGGGGGSIRAAGGAFGKLEAAREEEFFYKKQKEQLERLKNDQIHQAEFHHQQIKEHEEAIQRHKDFLNNLHK Fruit fly Cell membrane disintegration MTS/PES colorimetric assay MCF-7 Breast cancer IC50 : 50 μM
dbacp06125 SK84 SQLGDLGSGAGQGGGGGGSIRAAGGAFGKLEAAREEEFFYKKQKEQLERLKNDQIHQAEFHHQQIKEHEEAIQRHKDFLNNLHK Fruit fly Destroying the cell membranes Cell proliferation assay MCF-7 Breast cancer MIC : 4 – 8 mM
dbacp06140 SP22 ACHWPWCHGWHSACDLPMHPMC Not found Inducing apoptosis Tunnel assay MCF-7 Breast cancer Not found
dbacp06171 SVS-1 KVKVKVKVpPTKVKVKVK Synthetic peptide Disruption of cell membranes MTT/MTS assay MCF-7 Breast cancer IC50 : 8.1 ± 0.8 µM
dbacp06175 SVS-2 KVKVKVKVPPTKVKVKVK Synthetic peptide Disruption of cell membranes MTT/MTS assay MCF-7 Breast cancer IC50 : >100 µM
dbacp06187 t Mastoparan-C(tMP-C, Tat (49-57)-Mastoparan-C) RKKRRQRRRLNLKALLAVAKKIL Synthetic construct Apoptosis inducing MTT assay MCF-7 Human breast cancer IC50 : 3.70 μM
dbacp06220 TAT-RasGAP (317-326) From p120RasGAP GRKKRRQRRRGGWMWVTNLRTD Not found Inducing apoptosis Luciferase assay MCF-7 Human malignant mesothelomia Not found
dbacp06233 Temporin-1CEa FVDLKKIANIINSIF Chinese brown frog Membrane disruption MTT/MTS assay MCF-7 Breast cancer 61% cell viability at 40 µM
dbacp06234 Temporin-1CEa FVDLKKIANIINSIF Chinese brown frog Membrane disruption LDH leakage assay MCF-7 Breast cancer 32% cytotoxicity at 40 µM
dbacp06237 Temporin-1CEa FVDLKKIANIINSIF Chinese brown frog Membrane disruption MTT/MTS assay MCF-7 Breast cancer MIC : 40 µM
dbacp06238 Temporin-1CEa FVDLKKIANIINSIF Chinese brown frog Membrane disruption LDH leakage assay MCF-7 Breast cancer MIC : 40 µM
dbacp06242 Temporin-1RNa ILPIRSLIKKLL The black-spotted frog, Northeastern China, Asia Disruption of membrane Cytotoxicity assay, MTT/MTS assay MCF 7 Breast cancer IC50 : 23.4 ± 5.2 µM
dbacp06244 Temporin-1RNb FLPLKKLRFGLL The black-spotted frog, Northeastern China, Asia Disruption of membrane Cytotoxicity assay, MTT/MTS assay MCF 7 Breast cancer IC50 : 11.4 ± 2.3 µM
dbacp06295 Tetramer of peptide-paclitaxel conjugate (K-Aib-C(CH2CO-2'-Pac))4 Synthetic peptide paclitaxel conjugate Not specified MTT/MTS assay MCF-7 Breast cancer IC50 : 0.64 nM
dbacp06327 Transactivator of transcript-DV1-Bcl-2, AT-DV1-BH3 RRRQRRKKRGGGGLGASWHRPDK Transactivator of transcript-DV1-Bcl-2 TAT-DV1-BH4 Apoptosis inducing Cell viability assay, Transwell invasion assay MCF-7 Breast cancer Not specified
dbacp06348 Trimer of peptide-paclitaxel conjugate (K-Aib-C(CH2CO-2'-Pac))3 Synthetic peptide paclitaxel conjugate Not specified MTT/MTS assay MCF-7 Breast cancer IC50 : 3.00 nM
dbacp06362 TsAP-2 FLGMIPGLIGGLISAFK Venom-derived cDNAlibrary of the Brazilian yellow scorpion Not specified MTT/MTS assay MCF-7 Breast cancer IC50 : 6.4 µM
dbacp06370 TsAP-S1 FLSLIPKLVKKIIKAFK Derivative of TsAP-1, Brazilian yellow scorpion venom peptide Not specified MTT/MTS assay MCF-7 Breast cancer IC50 : 1.8 µM
dbacp06378 TsAP-S2 FLGMIPKLIKKLIKAFK Derivative of TsAP-1, Brazilian yellow scorpion venom peptide Not specified MTT/MTS assay MCF-7 Breast cancer IC50 : 1.8 µM
dbacp06416 U3 NGSIPATWASL Date palm Cell proliferation inhibition MTT/MTS assay MCF-7 Breast cancer IC50 : 555 μM
dbacp06419 U7 NCSIHGDIPAY Date palm Cell proliferation inhibition MTT/MTS assay MCF-7 Breast cancer IC50 : 554 μM
dbacp06534 wtmda-7/IL-24 MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSGAQGQEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQNVSDAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLANNFVLIVSQLQPSQENEMFSIRDSAHRRFLLFRRAFKQL Not found Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer Cell viability (% of control):0.5 at concentration 7 µg/ml
dbacp06536 wtmda-7/IL-24 MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSGAQGQEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQNVSDAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLANNFVLIVSQLQPSQENEMFSIRDSAHRRFLLFRRAFKQL Not found Apoptosis inducing MTT/MTS assay MCF-7 Breast cancer Apoptotic rate(%) : > 50% at concentration of 8 µg/ml
dbacp06543 XLAsp-P1 DEDDD Skin, African clawed frog, Africa Destruction of the cell membrane MTT assay MCF-7 cells Breast cancer LC50 : < 5 μg/mL
dbacp06565 Z24 ALSKALSKALSKALSKALSKALSK African clawed frog Dissipate ion gradients; Induce osmotic lysis; Membrane damage Trypan blue assay MCF-7 Breast cancer Not found
dbacp06581 Z44 ALSKALSKALSKALSKALSKALSK African clawed frog Dissipate ion gradients;Induce osmotic lysis; Membrane damage Trypan blue assay MCF-7 Breast cancer Not found
dbacp06616 LA3IK LAIAVK Migration and invasion enhancer 1 (MIEN1) Targeting the MIEN1 signaling pathway MTT assay MCF-7 Breast Cancer IC50 = 90.23 ± 7.32 µM
dbacp06620 D-LA3IK laiavk Migration and invasion enhancer 1 (MIEN1) Targeting the MIEN1 signaling pathway MTT assay MCF-7 Breast Cancer IC50 = 91.2 ± 8.21 µM
dbacp06624 LA3IK-SCR LAKAVI Migration and invasion enhancer 1 (MIEN1) Targeting the MIEN1 signaling pathway MTT assay MCF-7 Breast Cancer IC50 = 133 ± 9.52 µM
dbacp06628 RP-7 RPPCVIL Migration and invasion enhancer 1 (MIEN1) Targeting the MIEN1 signaling pathway MTT assay MCF-7 Breast Cancer IC50 = 110.12 ± 4.23 µM
dbacp06632 D-RP-7 rppcvil Migration and invasion enhancer 1 (MIEN1) Targeting the MIEN1 signaling pathway MTT assay MCF-7 Breast Cancer IC50 = 90 ± 10.31 µM
dbacp06636 RP7 SCR RPPLVIC Migration and invasion enhancer 1 (MIEN1) Targeting the MIEN1 signaling pathway MTT assay MCF-7 Breast Cancer IC50 = 150 ± 10.32 µM
dbacp06641 C-Mel CGIGAVLKVLTTGLPALISWIKRKRQQ Synthetic analogue Plasma memberane pore formation MTT assay MCF-7 Breast Cancer IC50 = 110.59 µg/mL
dbacp06644 CM–FA CGIGAVLKVLTTGLPALISWIKRKRQQ Synthetic analogue Plasma memberane pore formation MTT assay MCF-7 Breast Cancer IC50 = 10.38 µg/mL
dbacp06647 Mel-C GIGAVLKVLTTGLPALISWIKRKRQQC Synthetic analogue Plasma memberane pore formation MTT assay MCF-7 Breast Cancer IC50 = 160.62 µg/mL
dbacp06650 MC–FA GIGAVLKVLTTGLPALISWIKRKRQQC Synthetic analogue Plasma memberane pore formation MTT assay MCF-7 Breast Cancer IC50 = 12.63 µg/mL
dbacp06673 Crabrolin FLPLILRKIVTAL European hornet (Vespa crabro) Not available MTT assay MCF-7 Breast Cancer IC50 = 26.49 μM
dbacp06678 Crabrolin-4R FLPRILRKIVTAL Synthetic Analog of Crabrolin Not available MTT assay MCF-7 Breast Cancer IC50 = 20.26 μM
dbacp06683 Crabrolin-4K FLPKILRKIVTAL Synthetic Analog of Crabrolin Not available MTT assay MCF-7 Breast Cancer IC50 = 23.18 μM
dbacp06688 Crabrolin-TR FLPRILRKIVRAL Synthetic Analog of Crabrolin Not available MTT assay MCF-7 Breast Cancer IC50 = 3.459 μM
dbacp06693 Crabrolin-FR RLPRILRKIVRAL Synthetic Analog of Crabrolin Not available MTT assay MCF-7 Breast Cancer IC50 = 33.85 μM
dbacp06698 Crabrolin-AR RLPRILRKIVRRL Synthetic Analog of Crabrolin Not available MTT assay MCF-7 Breast Cancer IC50 = 32.51 μM
dbacp06703 Crabrolin-PR RLRRILRKIVRRL Synthetic Analog of Crabrolin Not available MTT assay MCF-7 Breast Cancer IC50 = 12.29 μM
dbacp06722 GE18 GAGIVVASIDTGVRVSHE Aphanomyces invadans Not available MTT assay MCF-7 Breast Cancer IC50 = 35.34 µM
dbacp06744 M1-20 grrrqrrkkrlgpfsidllikslsdnmtdl Synthetic Inhibits FOXM1 transcriptional activities CCK-8 assay MCF-7 Breast Cancer IC50 = 31.05 µM
dbacp06791 PS9 PSRKVMLWS Aphanomyces invadans Reactive Oxygen Species and Apoptotic Pathways Neutral Red Uptake assay MCF-7 Breast Cancer IC50 value range between 25.27 - 43.28 μM
dbacp06792 PS9 PSRKVMLWS Aphanomyces invadans Reactive Oxygen Species and Apoptotic Pathways LDH leakage assay MCF-7 Breast Cancer 71.25 ± 1.3% LDH release at 40 μM
dbacp06796 LHRH-BinBC QHWSYGLRPGGRGPKDAVRAVKGSALLPCIIVHDPNLNNSDKMKFNTYYLLEYKEYWHQLWSQIIPAHQTVKIQERTGISEVVQNSMIEDLNMYIGADFGMYFYLRSSGFKEQITRGLNRPLSQTTTQLGERVEEMEYYNSNDLDVRYVKYALAREFTLKRVNGEIVKNWVAVDYRMAGIQSYPNAPITNPLTLT Synthetic Apoptosis inducing MTT assay MCF-7 Breast Cancer IC50 = 10.96 μM
dbacp06797 LHRH-BinBC QHWSYGLRPGGRGPKDAVRAVKGSALLPCIIVHDPNLNNSDKMKFNTYYLLEYKEYWHQLWSQIIPAHQTVKIQERTGISEVVQNSMIEDLNMYIGADFGMYFYLRSSGFKEQITRGLNRPLSQTTTQLGERVEEMEYYNSNDLDVRYVKYALAREFTLKRVNGEIVKNWVAVDYRMAGIQSYPNAPITNPLTLT Synthetic Apoptosis inducing LDH leakage assay MCF-7 Breast Cancer 40% LDH efflux at 16 µM
dbacp06806 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MCF-7 Breast Cancer CC50 = 29.0 ± 3.7 μM
dbacp06812 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MCF-7 Breast Cancer CC50 = 15.2 ± 1.9 μM
dbacp06822 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MCF-7 Breast Cancer CC50 = 37.5 ± 3.3 μM
dbacp06828 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MCF-7 Breast Cancer CC50 = 6.7 ± 0.7 μM
dbacp06834 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MCF-7 Breast Cancer CC50 = 48.4 ± 0.7 μM
dbacp06840 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay MCF-7 Breast Cancer CC50 = 15.1 ± 1.4 μM
dbacp06870 LfcinB(21-25)Pal RWQWRWQWR LfcinB Apoptosis inducing MTT assay MCF-7 Breast Cancer IC50 = 81 µM
dbacp06871 RR-1-RR RRWQWRWQWRR Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MCF-7 Breast Cancer IC50 = 58 µM
dbacp06873 R-1-RR RWQWRWQWRR Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MCF-7 Breast Cancer IC50 = 122 µM
dbacp06875 RR-1-R RRWQWRWQWR Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MCF-7 Breast Cancer IC50 = 68 µM
dbacp06877 1 WQWRWQW Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MCF-7 Breast Cancer IC50 = 105 µM
dbacp06879 R-1 RWQWRWQW Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MCF-7 Breast Cancer IC50 = 58 µM
dbacp06881 1-R WQWRWQWR Synthetic analogue of LfcinB(21-25)Pal Apoptosis inducing MTT assay MCF-7 Breast Cancer IC50 = 130 µM
dbacp06925 #2(D33-N52) RRRRRRRRGGDRDYKKFWAGLQGLTIYFYN STAP-2 PH domain–derived peptide Inhibition of cell signalling CellTiter-Glo assay MCF-7 Breast Cancer Graph figure 1-B
dbacp06928 #6(M108-L127) RRRRRRRRGGMWKGFILTVVELRVPTDLTL STAP-2 PH domain–derived peptide Inhibition of cell signalling CellTiter-Glo assay MCF-7 Breast Cancer Graph figure 1-B
dbacp06978 C16-E4Y EEEEY Synthetic Inhibition of cell signalling WST-8 assay MCF-7 Breast Cancer 50 % cell viability at 0.05 wt %
dbacp07007 ST101 vaeareelerlearlgqargelkkwkmrrnqfwlklqr Synthetic Prevents C/EBPβ dimerization, induces degradation Annexin V/ PI staining assay MCF-7 Breast Cancer mean EC50 value of 2.1 ± 0.4 μmol/L
dbacp07023 [G10a]-SHa FLSGIVGMLaKLF Analog of temporin SHa Dendrimerization enhances stability, selectivity, anticancer efficacy Resazurin dye assay MCF-7 Breast Cancer IC50 = 15.05 ± 8.51 µM
dbacp07030 [G10a]2-SHa FLSGIVGMLaKLFKFLKaLMFLSGIVG Analog of temporin SHa Dendrimerization enhances stability, selectivity, anticancer efficacy Resazurin dye assay MCF-7 Breast Cancer IC50 = 5.69 ± 1.46 µM
dbacp07037 [G10a]3-SHa FLSGIVGMLaKLFFLSGIVGMLaKLFFLSGIVGMLaKLFKK Analog of temporin SHa Dendrimerization enhances stability, selectivity, anticancer efficacy Resazurin dye assay MCF-7 Breast Cancer IC50 = 3.77 ± 0.12 µM
dbacp07044 Jeff-[G10a]2-SHa FLSGIVGMLaKLF-jeff-FLSGIVGMLaKLF Analog of temporin SHa Dendrimerization enhances stability, selectivity, anticancer efficacy Resazurin dye assay MCF-7 Breast Cancer IC50 = 35.71 ± 8.50 µM
dbacp07110 Nigrocin-M1 GLLGKILGAGKKVLLGVSGLL Synthetic Membrane disruption mediates selective cytotoxicity. MTT assay MCF-7 Breast Cancer IC50 = 24.60 μM
dbacp07113 Galaxamide (N-Me-L)L(N-Me-L)LL Galaxaura filamentosa Cell-cycle arrest induces apoptosis MTT assay MCF-7 Breast Cancer IC50 = 11.33 ± 2.95 µg/ml
dbacp07117 Z-1 L(N-Me-L)LPL Synthetic Cell-cycle arrest induces apoptosis MTT assay MCF-7 Breast Cancer IC50 = 5.85 ± 1.28 µg/ml
dbacp07243 RB4 MADSERLSAPGCWAACTNFSRTRK Derived from protein PLP2 F-actin modulation induces necrotic death. MTT assay MCF-7 Breast Cancer EC50 = 0.724 ± 0.340 mol/L × 10-3
dbacp07283 AtMP1 THPPTTTTTTTTTTTTTAAPATTT Anabastestudineus skin mucus fraction 2 p53-mediated Bax/Bcl-2 apoptosis activation MTT assay MCF-7 Breast Cancer IC50 = 8.25 ± 0.14 μg/ml
dbacp07285 AtMP2 TGIATSGLATFTLHTGSLAPAT Anabastestudineus skin mucus fraction 2 p53-mediated Bax/Bcl-2 apoptosis activation MTT assay MCF-7 Breast Cancer IC50 = 5.89 ± 0.14 μg/ml
dbacp07310 LyeTxI-b IWLTALKFLGKNLGKLAKQQLAKL Synthetic Apoptosis induction and immune modulation. MTT assay MCF-7 Breast Cancer IC50 = 7.34 ± 3.09 µM
dbacp07315 B1OS-L FLPLIASLAGNVVPKIFCKITKRC B-1OS Not Available MTT assay MCF-7 Breast Cancer IC50 = 8.883 µM
dbacp07320 B1OS-D-L FlPLIASLAGNVVPKIFCKITKRC B-1OS Not Available MTT assay MCF-7 Breast Cancer IC50 = 3.17 µM
dbacp07347 GA - 2 Structure given in figure Synthetic (glycyrrhetinic acid (GA)-based peptides) Apoptosis induction, Bax/p53/caspase activation MTT assay MCF-7 Breast Cancer IC50 = 7.70 ± 1.3 µg/mL
dbacp07349 GA - 3 Structure given in figure Synthetic (glycyrrhetinic acid (GA)-based peptides) Apoptosis induction, Bax/p53/caspase activation MTT assay MCF-7 Breast Cancer IC50 = 5.1 ± 0.7 µg/mL
dbacp07351 GA - 4 Structure given in figure Synthetic (glycyrrhetinic acid (GA)-based peptides) Apoptosis induction, Bax/p53/caspase activation MTT assay MCF-7 Breast Cancer IC50 = 6.10 ± 0.4 µg/mL
dbacp07353 GA - 5 Structure given in figure Synthetic (glycyrrhetinic acid (GA)-based peptides) Apoptosis induction, Bax/p53/caspase activation MTT assay MCF-7 Breast Cancer IC50 = 5.0 ± 0.3 µg/mL
dbacp07355 GA - 7 Structure given in figure Synthetic (glycyrrhetinic acid (GA)-based peptides) Apoptosis induction, Bax/p53/caspase activation MTT assay MCF-7 Breast Cancer IC50 = 3.70 ± 0.2 µg/mL
dbacp07358 GA - 8 Structure given in figure Synthetic (glycyrrhetinic acid (GA)-based peptides) Apoptosis induction, Bax/p53/caspase activation MTT assay MCF-7 Breast Cancer IC50 = 6.90 ± 1.1 µg/mL
dbacp07363 Pal-N-Ter-TAT Pal-RDVFTKGYGFGL-GRK(Dansylglycine)KRRQRRRPQ Analogue of N-terminal fragment of the VDAC1 protein Mitochondrial targeting, VDAC1-HKII dissociation MTT assay MCF-7 Breast Cancer IC50 = 27.26 μM
dbacp07376 Brevinin-2DYd GIFDVVKGVLKGVGKNVAGSLLEQLKCKLSGGC Rana dybowskii Not Available MTT assay MCF-7 Breast Cancer IC50 = 25.74 µg/ml
dbacp07380 Ranatuerin-2Lb GILSSIKGVAKGVAKNVAAQLLDTLKCKITGC Rana luteiventris Not Available MTT assay MCF-7 Breast Cancer IC50 = 45.25 µM
dbacp07384 Odorranain-C1 GVLGAVKDLLIGAGKSAAQSVLKTLSCKLSNDC Odorrana grahami Not Available MTT assay MCF-7 Breast Cancer IC50 = 41.21 µM
dbacp07388 Brevinin-2DYb GLFDVVKGVLKGAGKNVAGSLLEQLKCKLSGGC Rana dybowskii Not Available MTT assay MCF-7 Breast Cancer IC50 = 37.84 µM
dbacp07392 Ranatuerin-2 GLFLDTLKGAAKDVAGKLEGLKCKITGCKLP Rana catesbeiana Not Available MTT assay MCF-7 Breast Cancer IC50 > 128 µM
dbacp07397 Pugnin A RLMRIFRILKLAR Synthetic Membrane disruption induces necrotic death MTT assay MCF-7 Breast Cancer 12% Cytotoxicity at 100 µM
dbacp07399 Pugnin B RMMRIFWVIKLAR Synthetic Membrane disruption induces necrotic death MTT assay MCF-7 Breast Cancer 5% Cytotoxicity at 100 µM
dbacp07403 Pep GKLRLIKKLWVKKWKKKGWKA Synthetic Membrane disruption induces necrotic death MTT assay MCF-7 Breast Cancer IC50 = 2 µM
dbacp07411 Si1 (KLAKLAK)2 Synthetic Membrane disruption induces cancer apoptosis MTT assay MCF-7 Breast Cancer IC50 = 124.1 ± 8.12 µM
dbacp07413 Si3 KL(Beta-A)KL(Beta-A)AK Synthetic Membrane disruption induces cancer apoptosis MTT assay MCF-7 Breast Cancer IC50 = 176.3 ± 4.66 µM
dbacp07414 Si2 KL(Beta-A)KL(Beta-A)K Synthetic Membrane disruption induces cancer apoptosis MTT assay MCF-7 Breast Cancer IC50 = 662.9 ± 20.02 µM
dbacp07417 Si11 KL(Beta-A)KLAK Synthetic Membrane disruption induces cancer apoptosis MTT assay MCF-7 Breast Cancer IC50 = 228.8 ± 7.18 µM
dbacp07418 Si13 KnLAKnLAK Synthetic Membrane disruption induces cancer apoptosis MTT assay MCF-7 Breast Cancer IC50 = 1704 ± 112 µM
dbacp07419 Si14 KnLAKnLAK Synthetic Membrane disruption induces cancer apoptosis MTT assay MCF-7 Breast Cancer IC50 = 593.3 ± 60.3 µM
dbacp07421 Si15 KnLAKnLAK Synthetic Membrane disruption induces cancer apoptosis MTT assay MCF-7 Breast Cancer IC50 = 140.3 ± 7.12 µM
dbacp07432 [Arg]3-VmCT1 FLRALWNVAKSVF Synthetic Membrane disruption via cationic interaction MTT assay MCF-7 Breast Cancer IC50 = 20.6 ± 3.1 μmol/L
dbacp07433 [Arg]7-VmCT1 FLGALWRVAKSVF Synthetic Membrane disruption via cationic interaction MTT assay MCF-7 Breast Cancer IC50 = 18.0 ± 2.7 μmol/L
dbacp07434 [Arg]11-VmCT1 FLGALWNVAKRVF Synthetic Membrane disruption via cationic interaction MTT assay MCF-7 Breast Cancer IC50 = 25.8 ± 5.2 μmol/L
dbacp07440 A4K14 - Citropin 1.1 - Sp 7 GLFAVR8KKVASVS5KGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay MCF-7 Breast Cancer IC50 = 12.1 µM
dbacp07444 A4K14 - Citropin 1.1 - Sp 6 GR8FAVIKKS5ASVIKGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay MCF-7 Breast Cancer IC50 = 23.78 µM
dbacp07448 A4K14 - Citropin 1.1 - Sp 5 GLFAVIKKVAS5VIKS5L Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay MCF-7 Breast Cancer IC50 = 12.42 µM
dbacp07452 A4K14 - Citropin 1.1 - Sp 4 GLFAVIKKS5ASVS5KGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay MCF-7 Breast Cancer IC50 = 10.49 µM
dbacp07456 A4K14 - Citropin 1.1 - Sp 3 GLFAVS5KKVS5SVIKGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay MCF-7 Breast Cancer IC50 = 11.92 µM
dbacp07460 A4K14 - Citropin 1.1 - Sp 2 GLFAS5IKKS5ASVIKGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay MCF-7 Breast Cancer IC50 = 12.65 µM
dbacp07464 A4K14 - Citropin 1.1 - Sp 1 GS5FAVS5KKVASVIKGL Synthetic Stapled peptide enhances helical apoptosis CCK-8 assay MCF-7 Breast Cancer IC50 = 11.26 µM
dbacp07473 MzDef MSSSNCANVCQTENFPGGECKAEGATRKCFCKNC Zea mays L. Disulfide-stabilized peptide disrupts pathogens MTT assay MCF-7 Breast Cancer IC50 = 14.85 µg/mL
dbacp07475 Latcripin-7A MTTESKVKNATTLLHSGKVKERQEGLSALRNIFSQNSSIERFYNVAGRDGRKPSHEIWAPILDGLQTCIRSEKSAFVTAKKSTDVIEKRLAAAAGTYRWFVEKSMMHFAKKTVLEICHFLYREMKVRETLIPSVALDFIKAYECVASHPPHLARLEEDEIEWEE Lentinula edodes Cell-cycle arrest, apoptosis, autophagy induction CCK-8 assay MCF-7 Breast Cancer IC50 = 91 μg/mL
dbacp07491 Figainin 1 FIGTLIPLALGALTKLFK Boana raniceps Membrane disruption, α-helix mediated MTT assay MCF-7 Breast Cancer IC50 = 13.7 µM
dbacp07496 RA-3 RWrGGGGGLFDIIKKIAESF Synthetic Integrin-targeting, α-helix mediated lysis MTT assay MCF-7 Breast Cancer IC50 = 44.14 μM
dbacp07500 Mambalgin-1 LKCYQHGKVVTCHRDMKFCYHNTGMPFRNLKLILQGCSSSCSETENNKCCSTDRCNK Dendroaspis polylepsis ASIC inhibition suppresses cancer proliferation MTT assay MCF-7 Breast Cancer 22.43% cytotoxicity at 10 µg/mL
dbacp07510 cyclic dipeptide - 2b WA Synthetic Not Available MTT assay MCF-7 Breast Cancer IC50 = 45.6 µM
dbacp07513 Dermaseptin-PP ALWKDMLKGIGKLAGKAALGAVKTLV Phyllomedusa palliata Membrane disruption triggers dual apoptosis MTT assay MCF-7 Breast Cancer IC50 = 2.92 μM
dbacp07534 rCT-II LKCKKLVPLFSKTCPAGKNLCYKMFMVAAPHVPVKRGCIDVCPKSSLLVKYVCCNTDKCN Naja naja Apoptosis via intrinsic (mitochondrial) and extrinsic (death receptor) pathways MTT assay MCF-7 Breast Cancer IC50 = 3.66 µg/mL
dbacp07552 macrocyclic pyridoheptapeptide derivative 1a Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay MCF-7 Breast Cancer IC50 = 15.329 ± 0.672 μM
dbacp07554 macrocyclic pyridoheptapeptide derivative 1b Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay MCF-7 Breast Cancer IC50 = 10.904 ± 0.534 μM
dbacp07556 macrocyclic pyridoheptapeptide derivative 1c Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay MCF-7 Breast Cancer IC50 = 34.894 ± 1.273 μM
dbacp07559 macrocyclic pyridoheptapeptide derivative 2b Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay MCF-7 Breast Cancer IC50 = 20.697 ± 0.974 μM
dbacp07561 macrocyclic pyridoheptapeptide derivative 2c Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay MCF-7 Breast Cancer IC50 = 24.943 ± 1.082 μM
dbacp07563 macrocyclic pyridoheptapeptide derivative 3a Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay MCF-7 Breast Cancer IC50 = 10.316 ± 0.546 μM
dbacp07565 macrocyclic pyridoheptapeptide derivative 3b Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay MCF-7 Breast Cancer IC50 = 9.911 ± 0.491 μM
dbacp07567 macrocyclic pyridoheptapeptide derivative 3c Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay MCF-7 Breast Cancer IC50 = 22.864 ± 0.992 μM
dbacp07569 macrocyclic pyridoheptapeptide derivative 4a Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay MCF-7 Breast Cancer IC50 = 9.304 ± 0.536 μM
dbacp07571 macrocyclic pyridoheptapeptide derivative 4b Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay MCF-7 Breast Cancer IC50 = 9.188 ± 0.545 μM
dbacp07573 macrocyclic pyridoheptapeptide derivative 4c Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay MCF-7 Breast Cancer IC50 = 19.552 ± 1.032 μM
dbacp07638 branched tetrapeptide Schiff bases derivative 4a Figure given in Scheme 1 Synthetic p53 stabilization and LDHA inhibition MTT assay MCF-7 Breast Cancer IC50 between 8.12 ± 0.14 to 17.55 ± 0.27 μM
dbacp07639 branched tetrapeptide Schiff bases derivative 4b Figure given in Scheme 1 Synthetic p53 stabilization and LDHA inhibition MTT assay MCF-7 Breast Cancer IC50 between 8.12 ± 0.14 to 17.55 ± 0.27 μM
dbacp07640 branched tetrapeptide Schiff bases derivative 4c Figure given in Scheme 1 Synthetic p53 stabilization and LDHA inhibition MTT assay MCF-7 Breast Cancer IC50 between 8.12 ± 0.14 to 17.55 ± 0.27 μM
dbacp07641 branched tetrapeptide Schiff bases derivative 5c Figure given in Scheme 1 Synthetic p53 stabilization and LDHA inhibition MTT assay MCF-7 Breast Cancer IC50 between 8.12 ± 0.14 to 17.55 ± 0.27 μM
dbacp07642 branched tetrapeptide Schiff bases derivative 5d Figure given in Scheme 1 Synthetic p53 stabilization and LDHA inhibition MTT assay MCF-7 Breast Cancer IC50 between 8.12 ± 0.14 to 17.55 ± 0.27 μM
dbacp07643 branched tetrapeptide Schiff bases derivative 5e Figure given in Scheme 1 Synthetic p53 stabilization and LDHA inhibition MTT assay MCF-7 Breast Cancer IC50 between 8.12 ± 0.14 to 17.55 ± 0.27 μM
dbacp07647 AP1-Z1 FLFSLIPHAISGLISAFK AcrAP1 from the venom of the Arabian scorpion Charge–hydrophobicity balance drives apoptosis MTT assay MCF-7 Breast Cancer IC50 = 7.222 μM
dbacp07650 AP1-Z5a FLFKLIPKAIKGLIKAFK Mutant of APR-Z1 Charge–hydrophobicity balance drives apoptosis MTT assay MCF-7 Breast Cancer Graph Figure 2A
dbacp07653 AP1-Z5b FLFKLIKHAIKGLIKAFK Mutant of APR-Z1 Charge–hydrophobicity balance drives apoptosis MTT assay MCF-7 Breast Cancer IC50 = 1.037 μM
dbacp07656 AP1-Z3a FLFSLIKHAIKGLISAFK Mutant of APR-Z1 Charge–hydrophobicity balance drives apoptosis MTT assay MCF-7 Breast Cancer Graph Figure 2A
dbacp07659 AP1-Z3b FLFSLIKHAISKLISAFK Mutant of APR-Z1 Charge–hydrophobicity balance drives apoptosis MTT assay MCF-7 Breast Cancer Graph Figure 2A
dbacp07662 AP1-Z7 FLFKLIKKAIKKLIKAFK Mutant of APR-Z1 Charge–hydrophobicity balance drives apoptosis MTT assay MCF-7 Breast Cancer Graph Figure 2A
dbacp07665 AP1-Z9 FLFKLIKKKIKKLIKKFK Mutant of APR-Z1 Charge–hydrophobicity balance drives apoptosis MTT assay MCF-7 Breast Cancer Graph Figure 2A
dbacp07808 cT1 KWCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay MCF-7 Breast Cancer CC50 = 6.4 ± 0.6 µM
dbacp07849 Dermaseptin-PT9 GLWSKIKDAAKTAGKAALGFVNEMV Phyllomedusa tarsius Membrane disruption and cationic enhancement MTT assay MCF-7 Breast Cancer IC50 = 7.44 µM
dbacp07854 K8, 23-DPT9 GLWSKIKKAAKTAGKAALGFVNKMV Synthetic Membrane disruption and cationic enhancement MTT assay MCF-7 Breast Cancer IC50 = 8.64 µM
dbacp07859 HN-1 FALGAVTKLLPSLLCMITRKC Amolops hainanensis Apoptosis induction and immune activation MTT assay MCF-7 Breast Cancer IC50 = 6.9 μM
dbacp07887 ICD-85 Not Available Active fractions from Gloydius halys and Hemiscorpius lepturus Caspase-9 mediated apoptotic death MTT assay MCF-7 Breast Cancer IC50 = 36.45 ± 0.38 μg/mL
dbacp07888 ICD-85 Not Available Active fractions from Gloydius halys and Hemiscorpius lepturus Caspase-9 mediated apoptotic death Neutral Red Uptake assay MCF-7 Breast Cancer IC50 = 21.97 ± 0.63 μg/mL
dbacp07931 myristoyl-CM4 GRWKIFKKIEKVGQNIRDGIVKAGPAVAVVGQAATI Bombyx mori Cell penetration, Mitochondrial dysfunction, Apoptosis pathway activation MTT assay MCF-7 Breast cancer IC50 = 6 μM
dbacp07944 TC22 MTVVLLLIVLPLLGGVHSSGIL Tribolium castaneum ROS, p53, mitochondrial apoptosis activation MTT assay MCF-7 Breast Cancer Fig 4a
dbacp07955 S-24-R2PLx GIMDTVKNAAKNLAGQLLDKLKCSITAC Synthetic Analogue of Ranatuerin-2PLx R2PLx induces caspase-dependent apoptosis MTT assay MCF-7 Breast Cancer IC50 = 316.90 µM
dbacp07958 Compound 2a Structure in scheme 1 Synthetic 5c inhibits cancer via kinase blockade Not Available MCF-7 Breast Cancer IC50 = 31.64 ± 1.30 µM
dbacp07960 Compound 2b Structure in scheme 1 Synthetic 5c inhibits cancer via kinase blockade Not Available MCF-7 Breast Cancer IC50 = 32.58 ± 1.50 µM
dbacp07964 Compound 3b Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available MCF-7 Breast Cancer IC50 = 25.33 ± 1.18 µM
dbacp07966 Compound 3c Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available MCF-7 Breast Cancer IC50 = 29.55 ± 2.06 µM
dbacp07969 Compound 4b Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available MCF-7 Breast Cancer IC50 = 10.45 ± 1.33 µM
dbacp07971 Compound 4c Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available MCF-7 Breast Cancer IC50 = 29.15 ± 1.39 µM
dbacp07973 Compound 5a Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available MCF-7 Breast Cancer IC50 = 12.67 ± 2.40 µM
dbacp07975 Compound 5b Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available MCF-7 Breast Cancer IC50 = 11.32 ± 1.15 µM
dbacp07977 Compound 5c Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available MCF-7 Breast Cancer IC50 = 9.41 ± 1.25 µM
dbacp07979 Compound 6a Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available MCF-7 Breast Cancer IC50 = 11.83 ± 1.62 µM
dbacp07981 Compound 6b Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available MCF-7 Breast Cancer IC50 = 10.87 ± 1.10 µM
dbacp07993 [G10a]SHa FLSGIVGMLaKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay MCF-7 Breast Cancer IC50 = 16.2 ± 2.2 µM
dbacp07996 [G10a]SHa-BCTP FLSGIVGMLaKLFLFKQYAELW Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay MCF-7 Breast Cancer IC50 = 26.85 ± 1.85 µM
dbacp07999 [G4a]SHa FLSaIVGMLGKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay MCF-7 Breast Cancer IC50 = 17.9 ± 1.1 µM
dbacp08002 [G7a]SHa FLSGIVaMLGKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay MCF-7 Breast Cancer IC50 =22.4 ± 2.2 µM
dbacp08005 [G4,7a]SHa FLSaIVaMLGKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay MCF-7 Breast Cancer IC50 = 29.5 ± 6.03 µM
dbacp08008 [G4,7,10a]SHa FLSaIVaMLaKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay MCF-7 Breast Cancer IC50 = 26.33 ± 5.8 µM
dbacp08011 [G7,10a]SHa FLSGIVaMLaKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay MCF-7 Breast Cancer IC50 = 21.3 ± 1.13 µM
dbacp08081 Peptide 3a YD Synthetic Inhibit COX-2 enzyme MTT assay MCF-7 Breast Cancer IC50 = 17.5 ± 0.04 µM
dbacp08086 L-K6 IKKILSKIKKLLK Temporin 1CEb analogue L-K6 binds, internalizes, damages nucleus MTT assay MCF-7 Breast Cancer IC50 = 31 μM
dbacp08090 B1 KKLFKKILKYLK Analogue of BP 100 Membrane disruption triggers apoptosis MTT assay MCF-7 Breast Cancer IC50 = 15.7 ± 1.5 μM
dbacp08091 B1 KKLFKKILKYLK Analogue of BP 100 Membrane disruption triggers apoptosis MTT assay MCF-7/ADM Breast Cancer IC50 = 18.2 ± 1.3 μM
dbacp08094 B2 KKLFKKILKYLKK Analogue of BP 100 Membrane disruption triggers apoptosis MTT assay MCF-7 Breast Cancer IC50 = 30.8 ± 3.4 μM
dbacp08095 B2 KKLFKKILKYLKK Analogue of BP 100 Membrane disruption triggers apoptosis MTT assay MCF-7/ADM Breast Cancer IC50 = 36.1 ± 6.7 μM
dbacp08098 B3 KKLFKKILKYLKKL Analogue of BP 100 Membrane disruption triggers apoptosis MTT assay MCF-7 Breast Cancer IC50 = 25.3 ± 3.2 μM
dbacp08099 B3 KKLFKKILKYLKKL Analogue of BP 100 Membrane disruption triggers apoptosis MTT assay MCF-7/ADM Breast Cancer IC50 = 28.4 ± 3.1 μM
dbacp08101 B5 LKKLFKKILKYLK Analogue of BP 100 Membrane disruption triggers apoptosis MTT assay MCF-7 Breast Cancer IC50 = 27.3 ± 2.4 μM
dbacp08102 B5 LKKLFKKILKYLK Analogue of BP 100 Membrane disruption triggers apoptosis MTT assay MCF-7/ADM Breast Cancer IC50 = 28.2 ± 2.7 μM
dbacp08105 B6 LKKLFKKILKYLKK Analogue of BP 100 Membrane disruption triggers apoptosis MTT assay MCF-7 Breast Cancer IC50 = 18.4 ± 1.5 μM
dbacp08106 B6 LKKLFKKILKYLKK Analogue of BP 100 Membrane disruption triggers apoptosis MTT assay MCF-7/ADM Breast Cancer IC50 = 20.7 ± 1.6 μM
dbacp08109 B9 KLKKLFKKILKY Analogue of BP 100 Membrane disruption triggers apoptosis MTT assay MCF-7 Breast Cancer IC50 = 38.3 ± 2.5 μM
dbacp08110 B9 KLKKLFKKILKY Analogue of BP 100 Membrane disruption triggers apoptosis MTT assay MCF-7/ADM Breast Cancer IC50 = 30.6 ± 5.7 μM
dbacp08136 Laterosporulin10 (LS10) ACVNQCPDAIDRFIVKDKGCHGVEKKYYKQVYVACMNGQHLYCRTEGGPCQL Brevibacillus sp. strain SKDU10 Apoptosis inducing MTT assay MCF-7 Breast Cancer 40% cytotoxicity at 5 μM concentration
dbacp08137 Laterosporulin10 (LS10) ACVNQCPDAIDRFIVKDKGCHGVEKKYYKQVYVACMNGQHLYCRTEGGPCQL Brevibacillus sp. strain SKDU10 Apoptosis inducing LDH leakage assay MCF-7 Breast Cancer >80% LDH release at 15 μM
dbacp08143 MccJ25-18-4 GGAGHVPEYFVGIGTPISFYG-WxEAAYQrFL Synthetic Apoptosis inducing MTT assay MCF-7 Breast Cancer IC50 = 14.2 ± 1.5 μM
dbacp08150 CIGB-552 HARIKpTFRRlKWKYKGKFW Synthetic Not Available Sulforhodamine B assay MCF-7 Breast Cancer IC50 = 379.1 ± 8.6 µM
dbacp08170 Peptide - 1 GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK Synthetic Not Available CellTiter-Glo assay MCF-7 Breast Cancer IC50 = 6.2 µM
dbacp08182 Peptide - 2 GF(A6c)G(A6c)R(A6c)G(A6c)F(A6c)G(A6c)GR(A6c)RRRR Synthetic Not Available CellTiter-Glo assay MCF-7 Breast Cancer IC50 = 7.0 µM
dbacp08190 Peptide - 3 GF(A6c)G(A6c)Orn(A6c)G(A6c)F(A6c)G(A6c)GOrn(A6c)Orn-Orn- Orn- Orn Synthetic Not Available CellTiter-Glo assay MCF-7 Breast Cancer IC50 = 4.6 µM
dbacp08198 Peptide - 4 GF(A6c)G(A6c)Dab(A6c)G(A6c)F(A6c)G(A6c)GDab(A6c)Dab-Dab-Dab-Dab Synthetic Not Available CellTiter-Glo assay MCF-7 Breast Cancer IC50 = 3.0 µM
dbacp08206 Peptide - 6 GF(A5c)G(A5c)K(A5c)G(A5c)F(A5c)G(A5c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay MCF-7 Breast Cancer IC50 > 7.5 µM
dbacp08214 Peptide - 7 GF(A5c)G(A5c)R(A5c)G(A5c)F(A5c)G(A5c)GR(A5c)RRRR Synthetic Not Available CellTiter-Glo assay MCF-7 Breast Cancer IC50 > 7.5 µM
dbacp08222 Peptide - 8 GF(A6c)G(Tic)K(A6c)G(Tic)F(A6c)G(Tic)GK(Tic)KKKK Synthetic Not Available CellTiter-Glo assay MCF-7 Breast Cancer IC50 > 7.5 µM
dbacp08230 Peptide - 9 GF(A6c)G(Oic)K(A6c)G(Oic)F(A6c)G(Oic)GK(Oic)KKKK Synthetic Not Available CellTiter-Glo assay MCF-7 Breast Cancer IC50 > 7.5 µM
dbacp08238 Peptide - 10 GF(A5c)G(A6c)K(A5c)G(A6c)F(A5c)G(A6c)GK(A5c)KKKK Synthetic Not Available CellTiter-Glo assay MCF-7 Breast Cancer IC50 > 7.5 µM
dbacp08246 Peptide - 11 KKKKGF(A6c)G(A6c)K(A6c)G(A6c)F(A6c)G(A6c)GK(A6c) Synthetic Not Available CellTiter-Glo assay MCF-7 Breast Cancer IC50 = 7.3 µM
dbacp08254 Tr1 Not Available Protein extraction from Spirulina platensis Not Available MTT assay MCF-7 Breast Cancer IC50 = 60.12 μg/mL
dbacp08256 Tr2 Not Available Protein extraction from Spirulina platensis Not Available MTT assay MCF-7 Breast Cancer IC50 < 31.25 μg/mL
dbacp08260 Tr4 Not Available Protein extraction from Spirulina platensis Not Available MTT assay MCF-7 Breast Cancer IC50 = 238.86 μg/mL
dbacp08299 SKACP003 FPLPCAYKGTYC Synthetic Not Available MTT assay MCF-7 Breast Cancer IC50 = 193 ± 0.5 µM
dbacp08380 IDP-LS13 RKRRNDLRSRFLALRDQ Synthetic Not Available MTT/Alamamar-Blue/Hexosaminidase activity test MCF-7 Breast Cancer EC50 ~ 10 μM
dbacp08424 5-2C NYPQRPCRGDKGPDC Synthetic Not Available MTT assay MCF-7 Breast Cancer IC50 = 9.74 μM